Skip to main content

Table 3 Proportions of patients (%) in each treatment group with reductions from baseline in HDL-C < and ≥30% at endpoint

From: Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin

Treatment Group

<30%

≥30%

PBO

55/55 (100)

0

FENO

49/51 (96)

2/51 (4)

EZE+FENO

16/17 (94)

1/17 (6)

EZE/SIMVA+FENO

16/16 (100)

0

  1. EZE = ezetimibe; FENO = fenofibrate; PBO = placebo; SIMVA = simvastatin
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X